Tagged with investment

pharma The general manager of Astellas France and president of LEEM, the French Pharmaceutical Companies Association, reveals how the pharmaceutical industry worldwide has to take into account what is a fair price for innovation, the sum of a value price, based on what you are providing for the health of a…

Pharma The phasing out of fiscal incentives in 2006 has impacted the Puerto Rican economy as well as the life science arena. The president of DDD Group, a company offering fully integrated services for capital project delivery, discusses the new challenges the industry is facing in terms of construction as well…

Pharma OrganoPlates™ serve as a highly useable platform for 3D cell cultures, are completely compatible with existing lab equipment, and can be used to develop true ‘organ-on-a-chip’ models. Co-founders of the developer and manufacturer, Mimetas, discuss the impact this product is already having on the drug development process, and its potential…

Pharma Yves Bur reveals how the motivation behind his political engagement has been to raise awareness around the importance of improving the social security system. Bur also explains why having a real public health policy is another way of combatting the increase in health spending, and how France needs to reach…

Pharma Skanska Puerto Rico’s Ramon Navia discusses the challenges the sector has faced in recent years and how Skanska has adapted its services portfolio to better cater to local clients’ needs. Skanska provides world-class construction management services to the life science industry.  What differentiates Skanska from other competitors and makes the group the…

Turkey Multinational R&D investment in Turkey, particularly investment in clinical trials, has been quite limited relative to the size of the Turkish pharmaceutical market. Turkish R&D spending amounted to just 0.95 percent of GDP last year, but the country plans to reach three percent of GDP by 2023. Multinational R&D investment…

Turkey In the coming years, Turkey plans to prioritize R&D initiatives, health studies and medical innovation: that’s the core message Minister of Health Mehmet Müezzinoğlu gave PharmaBoardroom. This is the beginning of a new era for healthcare in Turkey. The twenty-first century has already been a period of change in the…

Chiesi Chiesi is preparing to market two first in class products: the first approved stem cell treatment in Europe, and the first approved gene-therapy, developed in the Netherlands by partner UniQure. General Manager Nether Maurits Huigen discusses the challenges his affiliate is facing to bringing these pioneering products to market, along…

manufacturing The chancellor of the Medical Sciences Campus of the University of Puerto Rico discusses the medical R&D projects the university is currently involved in, the fields in which the island has the most potential, and how the institution is tailoring its academic offer to suit the local needs of the…

Puerto Rico Medical device manufacturer CMO C-Axis founded its facility in Puerto Rico in 2003. Jared Haley, the affiliate’s general manager, discusses new technologies and the company’s positioning within Puerto Rico’s growing medtech sector as a key service provider to the industry. Looking at C-Axis’s products and services here, what are the…

Generics The Moroccan pharma sector is increasingly looking not just to Europe, but also to Africa. Moroccan investment in distribution to African countries is increasing. But key opinion leaders say that challenges remain. For example, Morocco would benefit from a direct export platform. “In the past Morocco always looked towards the north…

healthcare In the past, the Moroccan pharmaceutical sector primarily served local needs. Now it is ramping up its research and development capabilities, looking outwards to global markets, developing partnerships with other African countries, and beginning to think about social programs such as public access to healthcare. “[Morocco’s] success grew from a…